CAJ | 학술논문

目的:观察美尔瑞片(中草药灯盏细辛)对眼压控制后的青光眼是否具有视神经保护作用.方法:对99例(113眼)眼压已控制的原发性开角型青光眼及闭角型青光眼进行多中心、前瞻性、随机、双盲对照临床研究,观察口服美尔瑞片6mo后对视野的疗效,本研究采用VFDS视野缺损计分法,从0(无缺损)至20(所有检测点均不可测出).结果:美尔瑞治疗组55例(66眼),安慰剂对照组44例(47眼),治疗前及治疗后2,4,6mo 2组的眼压均＜15mmHg,2组间同一时期眼压无显著性差异(P＞0.05).服美尔瑞2,4,6mo后VFDS净减值分别为0.44±1.60,1.27±2.16及1.42±2.37,呈现随治疗时间延长,视野缺损逐渐好转趋势.对照组2,4,6mo后VFDS净减计分值分别为-0.02±1.5,0.68±1.73和0.40±1.57.VFDS净减值两组间同一时期比较有显著性差异(P＜0.05),治疗6mo后有高度显著性差异(P＜0.01).结论:灯盏细辛可用于治疗青光眼性视神经病变,有助于扩大/保持视野.
목적:관찰미이서편(중초약등잔세신)대안압공제후적청광안시부구유시신경보호작용.방법:대99례(113안)안압이공제적원발성개각형청광안급폐각형청광안진행다중심、전첨성、수궤、쌍맹대조림상연구,관찰구복미이서편6mo후대시야적료효,본연구채용VFDS시야결손계분법,종0(무결손)지20(소유검측점균불가측출).결과:미이서치료조55례(66안),안위제대조조44례(47안),치료전급치료후2,4,6mo 2조적안압균＜15mmHg,2조간동일시기안압무현저성차이(P＞0.05).복미이서2,4,6mo후VFDS정감치분별위0.44±1.60,1.27±2.16급1.42±2.37,정현수치료시간연장,시야결손축점호전추세.대조조2,4,6mo후VFDS정감계분치분별위-0.02±1.5,0.68±1.73화0.40±1.57.VFDS정감치량조간동일시기비교유현저성차이(P＜0.05),치료6mo후유고도현저성차이(P＜0.01).결론:등잔세신가용우치료청광안성시신경병변,유조우확대/보지시야.
AIM: To evaluate the neuroprotective effects of a Chinese herbal drug, erigeron breviscapus (vant) hand-mass (EBHM), on glaucoma patients with controlled intraocular pressure (IOP) after surgical and/or medical therapies.METHODS: A total of 99 primary glaucoma patients (113 eyes) with medically or surgically controlled IOP were given orally either EBHM or placebo for 6 mo and then evaluated in a multi-center, prospective, randomized and double masked clinical trial by quantifying the visual field changes using visual field defect scoring (VFDS).RESULTS: After 2, 4, 6 mo of treatment, the VFDS in EBHM Group (66 eyes/55 patients) decreased by 0.44±1.60, 1.27±2.16 and 1.42±2.37 respectively, indicating a time-dependent improvement of visual field upon EBHM treatment, whereas the VFDS in Placebo Control Group (47 eyes/47 patients) decreased by -0.02±1.5, 0.68±1.73 and 0.40±1.57 respectively. Statistically, the differences in VFDS between the two groups were significant (P＜0.05) at 2 and 4mo, and highly significant at 6mo of treatment (P =0.007). The average IOP in both groups was 15mmHg (range 8-18mmHg) during the period of the study (P＞0.05). No serious side effects were reported in glaucoma patients on EBHM.CONCLUSION: EBHM appeared to be safe and effective in neuroprotection for patients with glaucoma. More studies are needed to determine the safety and effectiveness of longer-term EBHM treatment.